SG66226A1 - Process for producing preserved medicaments containing human proteins for the purposes of infusion or injection - Google Patents

Process for producing preserved medicaments containing human proteins for the purposes of infusion or injection

Info

Publication number
SG66226A1
SG66226A1 SG1996001887A SG1996001887A SG66226A1 SG 66226 A1 SG66226 A1 SG 66226A1 SG 1996001887 A SG1996001887 A SG 1996001887A SG 1996001887 A SG1996001887 A SG 1996001887A SG 66226 A1 SG66226 A1 SG 66226A1
Authority
SG
Singapore
Prior art keywords
preservative
prepn
infusion
injection
human protein
Prior art date
Application number
SG1996001887A
Other languages
English (en)
Inventor
Heinrich Woog
Werner Gruber
Hans-Jorg Markl
Gerhard Winter
Fritz Demmer
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6438353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG66226(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of SG66226A1 publication Critical patent/SG66226A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG1996001887A 1991-08-15 1992-08-10 Process for producing preserved medicaments containing human proteins for the purposes of infusion or injection SG66226A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4126983A DE4126983A1 (de) 1991-08-15 1991-08-15 Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke

Publications (1)

Publication Number Publication Date
SG66226A1 true SG66226A1 (en) 1999-07-20

Family

ID=6438353

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996001887A SG66226A1 (en) 1991-08-15 1992-08-10 Process for producing preserved medicaments containing human proteins for the purposes of infusion or injection

Country Status (25)

Country Link
US (2) US5503827A (ru)
EP (2) EP0528313A1 (ru)
JP (1) JP3670660B2 (ru)
KR (1) KR100263282B1 (ru)
AT (1) ATE145138T1 (ru)
AU (2) AU678756B2 (ru)
CA (1) CA2115348C (ru)
CZ (1) CZ284853B6 (ru)
DE (2) DE4126983A1 (ru)
DK (1) DK0607156T3 (ru)
ES (1) ES2094923T3 (ru)
FI (1) FI112169B (ru)
GE (1) GEP19981289B (ru)
GR (1) GR3022037T3 (ru)
HU (1) HU227421B1 (ru)
IL (1) IL102775A (ru)
MX (1) MX9204636A (ru)
NO (1) NO309844B1 (ru)
RU (1) RU2091068C1 (ru)
SG (1) SG66226A1 (ru)
SK (1) SK281910B6 (ru)
TW (1) TW351677B (ru)
UA (1) UA26343C2 (ru)
WO (1) WO1993003744A1 (ru)
ZA (1) ZA926122B (ru)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
JP3541054B2 (ja) * 1994-04-21 2004-07-07 ユニ・チャーム株式会社 使い捨ておむつ
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
PT1602667E (pt) * 1995-06-07 2007-07-13 Searle Llc Formulação aquosa que compreende tfpi e agentes de solubilização
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0784979A3 (en) * 1996-01-19 1999-03-03 Eli Lilly And Company Obesity protein formulations
JP2000504318A (ja) * 1996-01-19 2000-04-11 イーライ・リリー・アンド・カンパニー 肥満症タンパク質製剤
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
ES2179414T3 (es) * 1997-11-22 2003-01-16 Roche Diagnostics Gmbh Procedimiento mejorado de estabilizacion de proteinas.
EP1034269A1 (en) * 1997-11-28 2000-09-13 Roche Diagnostics GmbH An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
EP1060746A4 (en) * 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd PROTEIN-FREE PREPARATIONS
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
US6207718B1 (en) 1998-08-07 2001-03-27 Ontogeny, Inc. Pharmaceutical compositions containing hedgehog protein
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
RU2225221C2 (ru) * 1999-04-09 2004-03-10 Орто-Макнейл Фармасьютикал, Инк. ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ Эритропоэтина
CN101091792A (zh) * 1999-07-22 2007-12-26 阿温蒂斯药物公司 多剂量红细胞生成素制剂
KR20070116181A (ko) 1999-07-22 2007-12-06 아벤티스 파마슈티칼스 인크. 보존 제약 제형
TR200401573T4 (tr) 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
KR20050012224A (ko) * 2002-05-21 2005-01-31 다이이찌 산토리 파마 가부시키가이샤 그렐린 함유 의약 조성물
SI21257A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
US7812120B2 (en) * 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
AU2003901515A0 (en) * 2003-04-02 2003-04-17 Norika Holdings Sterilisation process for pharmaceutical product
EA009676B1 (ru) * 2003-06-10 2008-02-28 Эл Джи Лайф Сайенсиз Лтд. Водный препарат эритропоэтина человека
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7851433B2 (en) * 2003-08-13 2010-12-14 Novartis Vaccines And Diagnostics, Inc. Method of purifying TFPI and TFPI analogs
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CN101022822B (zh) * 2004-08-24 2012-06-27 第一三共株式会社 生理学活性肽的液体制剂
CA2915270C (en) * 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
PL2076243T3 (pl) 2007-08-27 2015-04-30 Ratiopharm Gmbh Płynna formulacja G-CSF
PT2197919E (pt) * 2007-08-27 2014-07-17 Ratiopharm Gmbh Formulação líquida de conjugado de g-csf
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
CN110433136A (zh) * 2008-02-08 2019-11-12 泰哈麦克斯总部英国有限公司 促卵泡激素的液体制剂
US8120369B2 (en) 2009-03-02 2012-02-21 Harris Corporation Dielectric characterization of bituminous froth
CN102548575A (zh) * 2009-09-25 2012-07-04 参天制药株式会社 滴眼剂
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
MA48047A (fr) * 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
KR20200143416A (ko) * 2018-04-09 2020-12-23 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 엑소좀을 사용하는 종양 유전자의 치료학적 표적화

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3106073A1 (de) * 1981-02-19 1982-08-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
WO1991001143A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Stable vaccine compositions containing interleukins
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions

Also Published As

Publication number Publication date
RU2091068C1 (ru) 1997-09-27
AU1633997A (en) 1997-05-22
FI940674A (fi) 1994-02-14
GEP19981289B (en) 1998-05-01
SK281910B6 (sk) 2001-09-11
ES2094923T3 (es) 1997-02-01
FI940674A0 (fi) 1994-02-14
US6303113B1 (en) 2001-10-16
AU2409492A (en) 1993-03-16
UA26343C2 (uk) 1999-08-30
DE4126983A1 (de) 1993-02-18
IL102775A (en) 1999-12-22
ATE145138T1 (de) 1996-11-15
EP0607156A1 (de) 1994-07-27
IL102775A0 (en) 1993-01-31
CA2115348A1 (en) 1993-03-04
HU227421B1 (en) 2011-05-30
SK14894A3 (en) 1994-11-09
DE59207523D1 (de) 1996-12-19
US5503827A (en) 1996-04-02
NO940499L (no) 1994-02-14
AU710768B2 (en) 1999-09-30
AU678756B2 (en) 1997-06-12
CZ284853B6 (cs) 1999-03-17
NO940499D0 (no) 1994-02-14
MX9204636A (es) 1993-02-01
DE59207523C5 (de) 2006-11-16
DK0607156T3 (da) 1997-04-07
TW351677B (en) 1999-02-01
HUT67379A (en) 1995-04-28
FI112169B (fi) 2003-11-14
ZA926122B (en) 1994-02-14
JP3670660B2 (ja) 2005-07-13
JPH06510031A (ja) 1994-11-10
CZ28794A3 (en) 1994-08-17
EP0607156B1 (de) 1996-11-13
HU9400416D0 (en) 1994-05-30
KR100263282B1 (ko) 2000-08-01
WO1993003744A1 (de) 1993-03-04
GR3022037T3 (en) 1997-03-31
CA2115348C (en) 2007-07-17
RU94016163A (ru) 1996-08-10
EP0528313A1 (de) 1993-02-24
NO309844B1 (no) 2001-04-09

Similar Documents

Publication Publication Date Title
GR3022037T3 (en) Process for producing preserved medicaments containing human proteins for the purposes of infusion or injection.
CS274681B2 (en) Method of erythropoietin's stabilized preparation production
JPS6490123A (en) Nitroglycerol spray agent
EP0299756A3 (en) Anti-acne composition
DE69329367D1 (de) Wachstumshormon-enthaltendeproteinformulierung
EP0747092A3 (en) Dissolution liquid for drug in iontophoresis
ES445542A1 (es) Procedimiento de obtencion de laminas de recubrimiento para aplicaciones cosmeticas.
IE38514L (en) Insulin preparations.
IT1243742B (it) Composizioni farmaceutiche a base di calcitonine
ES8802560A1 (es) Un metodo para la preparacion de derivados estables efervescentes de acido acetilsalicilico con propiedades antihistaminicas.
PT82277A (en) Method for enhancement of absorption of proteins with medicinal properties